Hetero, Cipla's Remdesivirs Hit India Market, 'Surplus' Envisaged By August
Prices Well Below $100/vial
Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.
